Evidence map›Paper›PMID 41444209›Full record

ReviewCell death discovery2025

Targeting mitochondrial autophagy for anti-aging.

Wenjun Shan, Yuling Liu, Ruying Tang, Hui Li, Hongjun Yang, Longfei Lin

Abstract readReview
In one paragraph

Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenjun Shan *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.ORCID http://orcid.org/0009-0009-3977-5982
Yuling Liu *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Ruying TangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Hui LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. lihuizys@126.com.
Hongjun YangChina Academy of Chinese Medical Sciences, Beijing, China. hongjun0420@vip.sina.com.
Longfei LinInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China. lflin@icmm.ac.cn.ORCID http://orcid.org/0009-0006-0204-2206

Funding

Beijing Nova Program 20230484300
6 · The paper itself

Abstract

Mitochondrial dysfunction is one of the core drivers of aging. It is manifested by reactive oxygen species (ROS) accumulation, mitochondrial DNA (mtDNA) mutations, imbalanced energy metabolism, and abnormal biosynthesis. Mitochondrial autophagy maintains cellular homeostasis by selectively removing damaged mitochondria through mechanisms including the ubiquitin-dependent pathway (PINK1/Parkin pathway) and the ubiquitin-independent pathway (mediated by receptors such as BNIP3/FUNDC1). During aging, the decrease in mitochondrial autophagy efficiency leads to the accumulation of damaged mitochondria, forming a cycle of mitochondrial damage-ROS-aging damage and aggravating aging-related diseases such as neurodegenerative diseases and cardiovascular pathologies. The targeted regulation of mitochondrial autophagy (drug modulation and exercise intervention) can restore mitochondrial function and slow aging. However, autophagy has a double-edged sword effect; moderate activation is anti-aging, but excessive activation or dysfunction accelerates the pathological process. Therefore, targeting mitochondrial autophagy may be an effective anti-aging technique; however, future focus should be on the tissue-specific regulatory threshold and the dynamic balance mechanism to achieve precise intervention.

Identifiers

PMID41444209
PMCPMC12876910

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.